2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
June 7th 2022
Selinexor generated a longer median progression-free survival compared with placebo in patients with advanced or recurrent endometrial cancer, including those with p53 wild-type tumors.
June 7th 2022
Adjuvant pembrolizumab was found to generally improve disease-free survival over placebo in patients with completely resected early-stage non–small cell lung cancer, irrespective of type of surgical resection, tumor size, and type or extent of adjuvant chemotherapy.
June 5th 2022
Adjuvant pembrolizumab was found to result in a significant improvement in distant metastasis-free survival compared with placebo, with a continued reduction in risk of recurrence and an acceptable safety profile, in patients with resected stage IIB or stage IIC melanoma.
May 14th 2022
Darolutamide was found to have a favorable safety and tolerability profile in patients with metastatic castration-resistant prostate cancer who were enrolled to the phase 1 ARAFOR study and received extended treatment with the agent for more than 4 years.
April 25th 2022
The use of ruxolitinib following an allogeneic hematopoietic cell transplantation was associated with the prevention of serious graft-versus-host disease.
April 11th 2022
The combination of nivolumab with chemotherapy elicited a higher overall survival rate compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of tumor mutational burden (TMB) status.
February 19th 2022
A reduction in cabozantinib dosage because of toxicity demonstrated improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.
February 18th 2022
Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT baseline functional imaging parameters and percent change in lesion number observed on follow-up imaging was linked with overall survival and found to be prognostic in patients with metastatic genitourinary cancers.
January 23rd 2022
The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.
January 22nd 2022
Trastuzumab deruxtecan demonstrated durable responses and a safety profile that was consistent with findings from the primary analysis of the phase 2 DESTINY-CRC01 trial in pretreated patients with HER2-expressing metastatic colorectal cancer, according to updated results of the study.
December 14th 2021
Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.
December 11th 2021
Parsaclisib demonstrated early and long-lasting responses in patients with BTK-naïve, relapsed/refractory marginal zone lymphoma, according to findings from the phase 2 CITADEL-204 trial.